TheEdgeResearch
Home / Stocks / NVCT

Nuvectis Pharma, Inc. (NVCT)

NASDAQ Healthcare Biotechnology
$19.39 ▼ -2.27%
Market Cap
$666.8M
Sector
Healthcare
Industry
Biotechnology
Beta
-0.24
52-Wk Range
5.77-29.28
CEO
Ron Bentsur
Country
US
Currency
USD

Nuvectis Pharma, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Fort Lee, NJ, US. The stock last traded at $19.39, down 2.27% on the session, giving a market capitalisation of $666.8M. On trailing twelve-month figures it carries a trailing P/E of -10.26, a net margin of 0.0%. Its beta of -0.24 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-10.26
Price / Sales
0.00
Price / Book
4.51
EV / EBITDA
-10.02
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.00
Current ratio
9.92
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
19
IPO date
2022-02-04
Headquarters
Fort Lee, NJ, US
About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.

Comparable companies

Nuvectis Pharma, Inc. is most often compared with the following Healthcare names:

CMPXIMMXIMRXJANXMGNXMREONUVBORICSNDXVSTM
More research on NVCT
NVCT technical analysis NVCT TheEdge Score Compare against peers
Open full interactive analysis & DCF →